









Markets
/
Stocks
/
nasdaq-blfs
/

BioLife Solutions Inc

BLFS

26.280USD

+0.695+2.72%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.26BMarket Cap

LossP/E TTM



BioLife Solutions Inc

26.280

+0.695+2.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

24 / 207

Overall Ranking

117 / 4723

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

31.300

Target Price

+20.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Growing

The company is in a growing phase, with the latest annual income totaling USD 82.25M.

Undervalued

The company’s latest PE is -244.88, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 47.71M shares, decreasing 10.17% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.89M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.90, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 25.42M, representing a year-over-year decrease of 10.26%, while its net profit experienced a year-over-year decrease of 23.56%.

Score

Industry at a Glance

Previous score

8.69

Change

0.21



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -244.88, which is -97.04% below the recent high of -7.25 and 90.75% above the recent low of -22.64.

Score

Industry at a Glance

Previous score

2.00

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.40, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for BioLife Solutions Inc is 31.00, with a high of 34.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

31.300

Target Price

+22.34%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

BioLife Solutions Inc

BLFS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.82, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 27.37 and the support level at 23.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.07

Change

-0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.242

Neutral

RSI(14)

59.265

Neutral

STOCH(KDJ)(9,3,3)

39.963

Neutral

ATR(14)

0.866

High Vlolatility

CCI(14)

40.750

Neutral

Williams %R

40.523

Buy

TRIX(12,20)

0.427

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

25.831

Buy

MA10

26.147

Buy

MA20

25.770

Buy

MA50

23.713

Buy

MA100

23.130

Buy

MA200

24.400

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 99.74%, representing a quarter-over-quarter decrease of 7.28%. The largest institutional shareholder is The Vanguard, holding a total of 2.89M shares, representing 6.03% of shares outstanding, with 1.61% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Casdin Capital, LLC

7.71M

-11.77%

BlackRock Institutional Trust Company, N.A.

5.07M

-2.71%

T. Rowe Price Investment Management, Inc.

1.35M

Invesco Advisers, Inc.

3.33M

+8.99%

The Vanguard Group, Inc.

Star Investors

2.80M

-1.14%

State Street Global Advisors (US)

1.43M

-2.40%

Fred Alger Management, LLC

1.53M

-3.83%

MFS Investment Management

764.67K

+0.23%

Rockefeller Capital Management

964.26K

+17.34%

Columbia Wanger Asset Management, LLC

881.34K

+18.04%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.45, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.